Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

被引:0
作者
T D Gould
J A Quiroz
J Singh
C A Zarate
H K Manji
机构
[1] Laboratory of Molecular Pathophysiology,
[2] National Institute of Mental Health,undefined
来源
Molecular Psychiatry | 2004年 / 9卷
关键词
depression; mania; pharmacology; manic-depressive illness; neurotrophic factors; valproic acid; PAP phosphatase; pramipexole; zinc;
D O I
暂无
中图分类号
学科分类号
摘要
Bipolar disorder afflicts approximately 1–3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: (1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); (2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site (inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
引用
收藏
页码:734 / 755
页数:21
相关论文
共 945 条
  • [21] Gandhi G(1999)Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3′-nucleotidase inhibited by inositol 1,4-bisphosphate J Biol Chem 274 13619-13628
  • [22] Edgell E(1982)Effects of lithium on the activities of phosphofructokinase and phosphoglucomutase and on glucose-1,6-diphosphate levels in rat muscles, brain and liver Biochem Pharmacol 31 1025-1031
  • [23] Revicki D(1984)Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase. Phosphorus NMR studies Biochemistry 23 252-260
  • [24] Evans DL(1978)The binding of lithium and of anionic metabolites to phosphoglucomutase Biochim Biophys Acta 522 434-442
  • [25] Charney DS(2001)Phosphoglucomutase is an J Biol Chem 276 37794-37801
  • [26] Nemeroff CB(1996) lithium target in yeast Proc Natl Acad Sci USA 93 8455-8459
  • [27] Muzina DJ(1996)A molecular mechanism for the effect of lithium on development Curr Biol 6 1664-1668
  • [28] El-Sayegh S(2002)Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells Pharmacol Ther 96 45-66
  • [29] Calabrese JR(2002)Lithium and valproic acid: parallels and contrasts in diverse signaling contexts Science 296 1644-1646
  • [30] Strakowski SM(2001)The promise and perils of Wnt signaling through beta-catenin Sci STKE 2001 RE12-776